A Phase II Study of Neo-adjuvant Erlotinib for Operable Stage IIB or IIIA Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activation Mutations.
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Aug 2017 Planned End Date changed from 1 Sep 2015 to 1 Sep 2020.
- 24 Aug 2017 Planned primary completion date changed from 1 Jun 2014 to 1 Sep 2019.
- 27 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.